ArticleJAMA oncology2019
Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be.
Article in JAMA oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Kinesin-related genes stratified the prognosis and immune responses of clear cell renal cell carcinoma.European journal of medical research · 2025Article
- Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.The oncologist · 2024Article
- Image-Guided Ablations in Patients with Recurrent Renal Cell Carcinoma.Journal of clinical medicine · 2023Article
- Exosomal circSPIRE1 mediates glycosylation of E-cadherin to suppress metastasis of renal cell carcinoma.Oncogene · 2023Article
- piRNA-1742 promotes renal cell carcinoma malignancy by regulating USP8 stability through binding to hnRNPU and thereby inhibiting MUC12 ubiquitination.Experimental & molecular medicine · 2023Article
- Compound C Inhibits Renca Renal Epithelial Carcinoma Growth in Syngeneic Mouse Models by Blocking Cell Cycle Progression, Adhesion and Invasion.International journal of molecular sciences · 2022Article
- Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.Current treatment options in oncology · 2022Review
- Article
- Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma.Frontiers in surgery · 2022Article
- Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma.Frontiers in genetics · 2022Article
- CircRNAs as Novel Biomarkers and Therapeutic Targets in Renal Cell Carcinoma.Frontiers in molecular biosciences · 2022Review
- Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma.Frontiers in cell and developmental biology · 2022Review
- Article
- circAMOTL1L Suppresses Renal Cell Carcinoma Growth by Modulating the miR-92a-2-5p/KLLN Pathway.Oxidative medicine and cellular longevity · 2021Article
- Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy.Molecular cancer · 2020Review
- circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma.Theranostics · 2020Article
- Stereotactic body radiation therapy for oligometastatic renal cell carcinoma: improving outcomes in an otherwise radioresistant malignancy.Annals of translational medicine · 2019Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30543365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.